Barber Daniel sold 25,000 Aquestive Therapeutics shares at $4.82 per share on Sep 15, 2026, leaving 652,317 shares. The transaction represented about 3.7% of his prior holding, giving investors the reported size of the sale relative to his position.
Key Highlights
- The transaction price was $4.82 per share.
- Barber Daniel is identified as Aquestive Therapeutics’ President and CEO.
- The sale carried transaction code S, denoting an open-market sale.
Barber Daniel sold 25,000 shares of Aquestive Therapeutics (NASDAQ: AQST) on Sep 15, 2026. The transaction involved the company’s President and CEO.
The transaction carried code S, which denotes an open-market sale in insider transaction reporting. The record classifies the activity as a sale rather than a purchase, award or grant. The reported price applies to each share included in the transaction.
3.7% of Prior Shareholding
The transaction represented about 3.7% of Daniel’s prior shareholding. Following the sale, his reported ownership stood at 652,317 shares. The percentage provides the stated comparison between the shares sold and Daniel’s position before the transaction. The remaining holding is expressed in shares of Aquestive Therapeutics.
FAQs
Q: What price did Barber Daniel receive for the Aquestive Therapeutics shares?
A: Barber Daniel sold the shares at $4.82 per share. The transaction involved 25,000 Aquestive Therapeutics shares and occurred on Sep 15, 2026.
Q: How large was Barber Daniel’s insider sale relative to his prior holding?
A: The sale represented about 3.7% of Barber Daniel’s prior shareholding. His reported ownership after the transaction was 652,317 shares.
Q: What does transaction code S mean in Barber Daniel’s sale?
A: Code S identifies an open-market sale in insider transaction reporting. It applies to Barber Daniel’s sale of Aquestive Therapeutics shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.